The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations

Cardiology in the Young

Volumn 15, Issue 3, 2005, Pages 251-255

  Rackham, Oliver J ^a,b   Thorburn, Kentigern ^a   Kerr, Steve J ^a  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^b ARROWE PARK HOSPITAL   (United Kingdom)

Author keywords

Infection; Paediatric cardiology; Palivizumab

Indexed keywords

ETANERCEPT; PALIVIZUMAB;

ARTICLE; BRONCHIOLITIS; CHILD; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; HEALTH ECONOMICS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; JUVENILE RHEUMATOID ARTHRITIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL RECORD; PATIENT REFERRAL; PATIENT TRANSPORT; PEDIATRICS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; BRONCHIOLITIS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; ENGLAND; HEART DEFECTS, CONGENITAL; HOSPITAL UNITS; HOSPITALIZATION; HUMANS; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; LENGTH OF STAY; PATIENT ADMISSION; PATIENT TRANSFER; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS;

EID: 25844513531     PISSN: 10479511     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1047951105000533     Document Type: Article

References (24)

1. Simoes EA. Respiratory syncytial virus infection. Lancet 1999; 354: 847-852.
2. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397-400.
3. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000; 137: 865-870.
4. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-540.
5. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child 2000; 83: 313-316.
6. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. A West Midlands Development and Evaluation Service Report. ISBN No. 0704423219. 2001. University of Birmingham.
7. Groothius JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329: 1524-1530.
8. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997; 99: 93-99.
9. Simoes EA, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998; 133: 492-499.
10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102: 531-537.
11. Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003; 13: 420-423.
12. Netton A, Rees T, Harrison G. Paramedic and emergency ambulance services. Unit Costs of Health and Social Care 2002. Personal Social Services Research Unit, University of Kent, Canterbury, 2002.
13. Joint Formulary Committee. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, 2003.
14. Edge WE, Kanter RK, Weigle CG, Walsh RF. Reduction of morbidity in interhospital transport by specialized pediatric staff. Crit Care Med 1994; 22: 1186-1191.
15. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004; 89: 961-965.
16. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002; 110: e53.
17. Connor EM, McClain JB, Sorrentino M, Hirsch RL, Top FH. Safety surveillance in children treated with palivizumab. J Perinatol 2002; 52: 619 (Abstract P33).
18. Mohan AK, Braun MM, Ellenberg S, Hedje J, Cote TR. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities. Pediatr Infect Dis J 2004; 23: 342-345.
19. Onuzo O. Re: Recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2004; 14: 469.
20. Handforth J, Sharland M, Friedland JS. Prevention of respiratory syncytial virus infection in infants. BMJ 2004; 328: 1026-1027.
21. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004; 114: 1606-1611.
22. Royal College of Nursing - pay awards. 2005. http://www.rcn.org.uk/resources/pay/.
23. Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004; 23: 318-322.
24. Rationing and the NHS. Drugs and Therapeutics Bulletin 2003; 41: 55-56.